Etanercept Market Size, Share, Growth Analysis, Forecast Report 2023-2030

Etanercept Industry Prospective:

The global etanercept market size was evaluated at $16.1 billion in 2022 and is slated to hit $31.1 billion by the end of 2030 with a CAGR of nearly 4% between 2023 and 2030.

Request Free Sample

Etanercept Market: Overview

Etanercept is a biopharmaceutical that is used to treat autoimmune disorders such as psoriatic arthritis, plaque psoriasis, juvenile idiopathic arthritis, rheumatoid arthritis, and ankylosing spondylitis. According to NCBI, it is a biological fusion protein interfering with tumor necrosis factor (TNF) by performing as a TNF inhibitor. It inhibits inflammatory response in joints and skin that characterizes autoimmune diseases. Reportedly, the medicine can also be utilized as monotherapy and consumed as immunosuppressants.

Key Insights

• As per the analysis shared by our research analyst, the global etanercept market is projected to expand annually at the annual growth rate of around 4% over the forecast timespan (2023-2030)
• In terms of revenue, the global etanercept market size was evaluated at nearly $16.1 billion in 2022 and is expected to reach $31.1 billion by 2030.
• The global etanercept market is anticipated to record massive growth over the forecast period owing to the growing incidence of spondylitis & rheumatoid arthritis, rising cases of obesity, a growing number of accidents, efforts taken by governments to create awareness regarding biopharmaceuticals, and FDA approval.
• In terms of drug type, the Benepali segment is slated to dominate the product type landscape in the upcoming years.
• Based on the application, the rheumatoid arthritis segment is anticipated to register the fastest CAGR over the projected period.
• Region-wise, the Asia-Pacific etanercept market is projected to register the fastest CAGR during the assessment timeline.

Etanercept Market: Growth Factors

A rise in the cases of spondylitis and rheumatoid arthritis will spike the global market growth

Factors such as growing incidence of spondylitis & rheumatoid arthritis, rising cases of obesity, a growing number of accidents, efforts taken by governments to create awareness regarding biopharmaceuticals, and FDA approval will act as major driving factors for the global etanercept market. Furthermore, growing healthcare expenditure and investment in research & development will act as a strong tool of growth for the market across the globe. A rise in lifestyle-related diseases such as diabetes, obesity, and high blood pressure will steer the global market expansion. In addition to this, an increase in the demand for drugs in treating autoimmune diseases such as plaque and rheumatoid arthritis will spur the business space. Key business strategies such as new product launches and partnerships adopted by market players for business expansion will contribute majorly towards the global market earnings. For instance, in August 2020, Lupin Limited, an Indian firm, and Mylan N.V., a generic & specialty pharmaceuticals firm based in the U.S., jointly introduced Nepexto, a biosimilar etanercept, in the pharmaceutical drug sector in Germany. For the record, the drug is used for treating rheumatoid arthritis, plaque psoriasis, and juvenile idiopathic arthritis.

Etanercept Market: Restraints

Strict laws related to safety over consumption of drugs can abridge their demand in the healthcare sector

Strict regulations related to the efficacy and safety of the etanercept will restrict the growth of the global etanercept industry. Apart from this, unfavorable compensation policies and huge treatment costs will put brakes on the global industry.  

Etanercept Market: Opportunities

An increase in healthcare investments will open new facets of growth for the global market by 2030

A rise in investments and strategic alliances in the healthcare sector will open new growth avenues for the global etanercept market. An increase in research activities related to the pharmaceutical industry and technological breakthroughs will culminate in the humungous expansion of the global market.

Etanercept Market: Challenges

Restrictions on the prescription of drugs in a few countries can create barricades in the global industry surge over the forecast period

Large out-of-pocket payments on healthcare spending along with the risk of lower treatment adherence will create a huge challenge for the global etanercept industry. Furthermore, restrictions on the use of the medicine in a few of the countries owing to its side effects can further impede the global industry demand.

Etanercept Market: Segmentation

The global etanercept market is sectored into drug type, application, and region.     

In drug type terms, the global etanercept market is segregated into Enbrel, Benepali, and others segments. Furthermore, the Benepali segment, which garnered nearly two-fifths of the global market share in 2022, is predicted to maintain its segmental domination in the forthcoming years. The growth of the segment in the ensuing years can be due to the efficacy of the drug in treating rheumatoid arthritis in comparison to other drug treatments.

Based on application, the global etanercept industry is bifurcated into juvenile idiopathic arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and others segments. Moreover, the rheumatoid arthritis segment, which contributed majorly towards the global industry revenue in 2022, is expected to register the fastest CAGR over the forecast timeframe. The segmental expansion over the estimated timespan can be subject to an increase in the frequency of rheumatoid arthritis occurrence in people, particularly middle-aged and geriatric populations across the globe.  

Etanercept Market: Report Scope

Etanercept Market: Regional Insights

North America is projected to maintain its global market dominance over the estimated timeframe

North America, which accounted for half of the global etanercept market revenue in 2022, will be the leading region over 2023-2030. Moreover, the regional market growth can be credited to the presence of key companies in countries such as the U.S., the rapid uptake of new treatments, and the accessibility of modern treatment options available in the region. Apart from this, the availability of skilled physicians in the region will further prompt the regional market surge. An increase in healthcare investments will steer the growth of the market in the sub-continent.

Moreover, the etanercept industry in Asia-Pacific is set to register a faster CAGR in the next couple of years subject to the growing patient awareness, high cases of rheumatoid arthritis, and increase in geriatric population prone to chronic disorders in the region. With an increase in the presence of contract research organizations in the region, the market in the Asia-Pacific is projected to witness notable growth in the years to come.

Etanercept Market: Competitive Space

The global etanercept market profiles key players such as:

• Pfizer Inc.
• GlaxoSmithKline Pharmaceuticals Ltd.
• Samsung Bioepis Co. Ltd.
• Novartis International AG
• Immunex Corporation
• F. Hoffmann-La Roche Ltd.
• Takeda Pharmaceutical Company Ltd.
• Cipla Limited
• Johnson & Johnson
• Celltrion Inc.

The global etanercept market is segmented as follows:

By Drug Type

• Enbrel
• Benepali
• Others

By Application

• Juvenile Idiopathic Arthritis
•  Rheumatoid Arthritis
• Psoriatic Arthritis
• Ankylosing Spondylitis
• Others

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa